Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INO 1001

Drug Profile

INO 1001

Alternative Names: INO-1001; Pardex; PARP inhibitors - Rocket

Latest Information Update: 09 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inotek Pharmaceuticals
  • Developer Genentech; Inotek Pharmaceuticals
  • Class Indoles; Vasoprotectives
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Reperfusion injury
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Abdominal aortic aneurysm; Acute lung injury; Erectile dysfunction; Glioblastoma; Malignant melanoma; Reperfusion injury

Most Recent Events

  • 04 Jan 2018 Rocket Pharmaceuticals merged with Inotek Pharmaceuticals and the combined company was named Rocket Pharmaceuticals
  • 11 Jan 2011 INO 1001 is available for licensing as of 11 Jan 2011. http://www.inotekcorp.com
  • 11 Jan 2011 Discontinued - Phase-I for Abdominal aortic aneurysm in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top